{"pub": "marketwatch", "url": "https://marketwatch.com/story/savara-shares-slide-48-premarket-after-fda-rejects-lung-disease-treatment-molgradex-2019-10-02?mod=rsswn", "downloaded_at": "2019-10-02 12:47:40.400316+00:00", "published_at": "2019-10-02", "title": "Savara shares slide 48% premarket after FDA rejects lung-disease treatment Molgradex", "language": "en", "text": "Shares of Savara Inc. SVRA, -6.42% tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S. Food and Drug Administration found data provided in a briefing package on its Molgradex program were not sufficient to submit a Biologics License Application. The Austin, Tx.-based copany said it is now working to determine its next steps for the program. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is in development for a range of lung conditions. \"While we are disappointed in the FDA's response, considering the IMPALA study results presented today at the ERS annual conference, we remain committed to the Molgradex development program and believe that it will provide aPAP patients with a meaningful treatment option,\" Chief Executive Rob Neville said in a statement. he was referring to data that was presented Wednesday at a Madrid meeting. Savara shares have fallen 67% in 2019, while the S&P 500 SPX, -1.23% has gained 17%.", "description": "Shares of Savara Inc. tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S. Food and Drug Administration found data...", "authors": ["Ciara Linnane", "Corporate News Editor"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"}